bluuebunny/crossref_metadata_2025_split huggingface dataset:
Depression of monocyte‐mediated cytotoxicity by renal carcinoma and restoration through therapy
Authors: Unsgaard Geirmund , Eggen Bjørn Magne , Lamvik Jon 
Published: February 2007

AbstractThe cytotoxic ability of freshly isolated monocytes against the tumor cell line K‐562 was severely depressed in patients with renal cell carcinoma. The impaired cytotoxicity was partly restored 2 weeks after nephrectomy. Production of monocyte‐activating lymphokine, measured as ability to activate tumor cytotoxicity in control monocytes, was depressed in lymphocytes from patients with tumor burden. The impaired lymphokine production seemed to be due to factors in patient serum. Patient monocytes showed an impaired ability to be activated by lymphokines. Products from patient lymphocytes were not able to activate the tumor cytotoxicity of patient monocytes.
Paget's disease of the male breast: A clinicopathologic study and a collective review
Authors: Gupta S. , Khanna N. N. , Khanna S. , Gupta S. 
Published: February 2007

AbstractTwo cases of Paget's disease of the male breast were detected in a retrospective histopathological review of 27 cases of male breast cancer treated during a period of 13 years from 1966 through 1978. The clinico‐pathological data on these two rare cases have been compared with the 23 histologically documented cases of Paget's disease of the male breast from the literature.
Relationship between body weight and the incidence of positive axillary nodes at mastectomy for breast cancer
Authors: Zumoff Barnett , Dasgupta Indira 
Published: February 2007

AbstractThe question, whether obesity is associated with an increased incidence of positive axillary nodes at mastectomy for breast cancer, was studied in two quite different hospital populations; one from a large urban teaching hospital (Montefiore) and one from a medium‐sized Air Force medical center (Malcolm Grow). In the Montefiore population, the answer was “yes”; 67% of the node‐positive patients, but only 31% of the nodenegative patients were obese (20% or more above ideal weight) (p < 0.05). In the Malcolm Grow population, the answer was “no”; 20% of the node‐positive and 20% of the node‐negative patients were obese. The different answers, we believe, are due to the biological differences between the populations; the Montefiore population was shorter (by an average of 1.7 inches), heavier (by an average of 20 lbs), and more obese. The incidence of obesity was about three times as high in the Montefiore population (52% versus 20%; p < 0.02) and it contained a statistically distinct subpopulation of obese patients, while the few obese patients in the Malcolm Grow population constituted merely the upper tail of a unimodal log‐normal distribution of weight in that population. We propose that it is possible to demonstrate a relationship of obesity to node‐positivity in the Montefiore population but not in the Malcolm Grow population because obesity was highly prevalent in the former and almost nonexistent in the latter. It seems self‐evident that it is not possible to demonstrate an effect of obesity in a population if that population manifests no significant obesity, statistically speaking, but disregarding this principle, we believe, may account for the controversy in the literature about whether obesity is a risk factor in breast cancer.
A modification of the (75se) selenomethionine assay for the detection of complement‐dependent antibody in human tumor systems
Authors: Avis Ingalill L. , Avis Frederick P. 
Published: February 2007

AbstractA modification of Brook's prelabeling (75SE) selenomethionine assay was developed and evaluated for detection of complement‐dependent antibody (CDA) in a human tumor system. CDA was indeed detected in some breast cancer patients' sera. To determine whether the assay was reliable and reproducible, xenoantibodies were raised in rabbits by immunization with a human breast cancer line, Sk‐Br‐3, and tested against that line and five other unrelated human cancer lines. Multiple tests were performed on separate days. It can be concluded from the data that the assay is reliable and reproducible. The assay has wide application in investigating the biologic role of complement‐dependent antibody activity in human and experimental animal tumor systems.
Development and evaluation of cancer chemotherapy drug information cards (DIC)
Authors: Khandekar Janardan D. 
Published: February 2007

AbstractCancer patients often receive multiple drugs. It is often difficult for them to differentiate between signs and symptoms caused by cancer from those induced by medications. Drug information cards (DIC) may serve a useful purpose to circumvent some of these problems. Here I describe DICs and their evaluation by patients. A vast majority (85%) of patients approved of these cards, and 67% would recommend them to others. I conclude that DICs are useful for cancer patients, and their role in nononcologic patients needs evaluation.
Carcinoembryonic antigen and interferon as tumor markers in breast cancer
Authors: Horn Yoav , Hacohen Dalia , Zeidman Jacob L. , Walach Natalio , Sharf Sally , Heller Adi , Salzberg Samuel 
Published: February 2007

AbstractA total of 239 determinations of CEA plasma levels were performed for 83 breast cancer patients during chemotherapy or follow‐up. In addition, 137 plasma samples were assayed for interferon levels. Patient clinical status was carefully scored according to objective criteria and recorded at each evaluation. Liver function tests (LFT) were performed to establish a full clinical picture at each visit. The results obtained proved a 73 to 83% positivity rate when the results of the 4 tests were compared. The importance of routine CEA assays and careful clinical evaluation and LFT are stressed. An analysis of interferon levels defined 4 distinct groups that differed by the amount of interferon present and also by clinical status and CEA levels. The results are discussed in terms of tumor volume‐dependent interferon production.
In vitro chemotherapy sensitivity testing of primary human colorectal carcinomas
Authors: Agrez Michael V. , Lieber Michael M. 
Published: February 2007

AbstractThe cells obtained from 138 tumor samples taken from 135 patients with colorectal malignancies were cultured in vitro in a soft agar colony formation assay similar to that of Salmon and colleagues [1]. Significant colony formation occurred for 63 (51%) of evaluable tumor cultures, 53 of which were also tested against chemotherapeutic agents in vitro. The median number of drugs tested per tumor was 15. Using 70% inhibition of colony formation as the criterion for significant drug‐induced cytotoxicity, only 3/53 (6%) of the tumors were noted to be sensitive to any drug. When colony counts generated by initially plated small tumor cell aggregates were taken into account, 8/40 (20%) of the tumors were noted to be sensitive in vitro to one or more agents. Because of the low rate of drug sensitivity found with this in vitro assay, its current role in the prospective assignment of chemotherapeutic treatment for patients with colorectal carcinoma is somewhat limited.
Cutaneous signs of internal malignancies
Authors: Helm Frederick 
Published: February 2007

AbstractThe more common paraneoplastic skin changes associated with internal malignancies (acanthosis nigricans, dermatomyositis, secondary ichthyosis) are discussed. The rare glucagonoma syndrome, consisting of alpha cell tumor of the pancreas, migratory necrolytic erythema, and diabetes mellitus, is described. The importance of recognition of these skin lesions may lead to early detection of the underlying cancer with possible cure.
Malignant fibrous histiocytoma of the gallbladder: A case report
Authors: Kristofferson Anders O. , Domellöf Lennart , Emdin Stefan O. , Kullenberg Krister 
Published: February 2007

AbstractA patient case with malignant fibrous histiocytoma (MFH) of the gallbladder is presented. This rare malignancy is occasionally found within the abdominal cavity. However, to our knowledge this is the first report of this tumor within the biliary tract. Diagnostic, therapeutic, and etiological aspects are discussed.
A Product report: Osto‐Zyme as an odor eliminator
Authors: Jackson Mildred , Kimmins Charlotte S. , Young Cynthia M. , Scarpino Lucia , Foster Sandra L. 
Published: February 2007

AbstractA product, Osto‐Zyme, was clinically tested at our Institute for the elimination of odor. Thirteen clients were chosen by enterostomal therapists to be tested. The product was sprayed directly into pouch, peristomal skin, and into night drainage units. This product proved very effective in the elimination of odor. The manufacturer of Osto‐Zyme is the Richard C. Shelton Co., Wright Brothers Branch, Dayton, Ohio.
Clinically significant intestinal metastasis from a primary bronchogenic carcinoma
Authors: Morris Don M. , Deitch Edwin A. 
Published: February 2007

AbstractAlthough abdominal metastasis from lung cancer are not unusual postmortem findings, they are rarely of clinical significance. Our patient's clinical course was complicated by intestinal obstruction secondary to metastatic lung cancer. With the current epidemic of lung cancer, we can expect more patients with abdominal complaints secondary to metastatic disease. In these patients, survival time averaged less than 60 days.
Long‐term survivors after adjuvant pelvic irradiation in rectal and sigmoid carcinoma: An assessment of late results
Authors: Kopelson Gene 
Published: February 2007

AbstractTwenty‐six patients with adenocarcinomas of the rectum, rectosigmoid, or sigmoid colon given adjuvant pre‐ or postoperative pelvic radiation therapy followed at least 5 years were retrospectively reviewed to evaluate late tumor control and complication rates. The overall 7‐year survival rate was 80 ± 8% with B2,3, patients faring better than C2,3 (94 ± 6% versus 43 ± 19%, p < 0.005). Local pelvic tumor control was achieved in 23/26 patients (88%); patients with high‐stage (C2,3) or poorly‐differentiated adenocarcinomas had a higher postirradiation pelvic relapse rate (3/11) versus low stage, well or moderately‐well differentiated tumors (0/15). A major complication (none fatal) occurred in 2 of 26 patients (8%) and was not correlated with either irradiation dose nor volume.Long‐term follow‐up is now available on patients who received adjuvant pelvic irradiation for rectal or sigmoid carcinomas and indicates a high pelvic tumor control rate. The 8% major complication rate may be decreased in the future by more sophisticated irradiation treatment planning.
Operative finding, treatment, and prognosis of carcinoma of the pancreas: An analysis of 267 cases
Authors: Appelqvist P. , Virén M. , Minkkinen J. , Kajanti M. , Kostiainen S. , Rissanen P. 
Published: February 2007

AbstractTwo hundred sixty‐seven laparotomized patients with pancreatic cancer during the period 1947 to 1980 were retrospectively analyzed. In 199 histologically confirmed cases of pancreatic carcinoma the tumor was only local with no invasion to neighboring tissues or distant metastases in 15% of the cases at the primary laparotomy and diagnosis stages, and the survival rates after 1, 3, and 5 years were 22%, 3% and 1%, respectively. The prognosis was a little better if a patient was over 70 years old, duration of symptoms was more than one year, the reason for laparotomy was cholecystopathy, the tumor was stage I, the treatment was a combination therapy of pancreatic resection and postoperative irradiation (with a depth dose of ≥ 4,000 rad). We concluded that, excluding the extremely rare cases of pancreatic carcinoma which are cured with pancreatic resection, the survival of patients after primary operation is correlated nearly in the same way with the given treatment and the stage of the disease. It seems that at present the only possibility of improving the results of treatment in pancreatic carcinoma is to develop the combined treatment of surgery, irradiation, and chemotherapy.
Breast carcinoma: Pattern of metastasis at autopsy
Authors: Lee Yeu‐Tsu N. (Margaret) 
Published: February 2007

AbstractBreast cancer is known to metastasize to all organs of the human body, and its manifestations are protean. It is almost impossible to predict which organ system will be invaded. Since 1950, there are seven autopsy series of patients with breast carcinoma published in the English literature. All data came from American hospitals (total of 2,147 patients), and each report studied more than 100 patients with breast cancer. The reported incidence of involvement of different organ sites are presented in Table I. Although the data came from different institutions and spanned over 35 years (1943–1977), the findings regarding metastatic involvement of specific organs are fairly similar.
Comparison of chemotherapy alone versus chemotherapy and radiation therapy of extensive small cell carcinoma of the lung
Authors: Wilson Henry E. , Stanley Kenneth , Vincent Ronald G. , Mountain Clifton F. , Sealy Rossall , Cohen Martin , Chen Tah Yee , Batley Frank , Kilman James , Kakos Gerard , Vasko John , Williams Thomas E. , Tucker Robert D. 
Published: February 2007

AbstractIn a randomized study 145 patients with extensive small cell carcinoma of the lung were treated with chemotherapy alone (Cytoxan, CCNU, methotrexate) or with the same drug regimen and with radiation therapy to the brain, chest, and abdomen. One hundred eighteen of these patients were evaluable. Those patients receiving radiation had a better response rate (55% vs 31%, P = .016) but significantly greater toxicity. There was no signficant difference in rates of complete response (7% vs 8%) or in survival (median 18.4 vs 15.3 weeks) between the two groups overall. The median survival of those patients with a partial resonse to therapy was 18 weeks; for those achieving a complete response it was 46 weeks. However, a clear difference in survival comparing responders with non‐responders was evident only for patients who were assigned to chemotherapy alone. Partial regressions have little, if any, correlation with improvement in survival. Therapy in this disease must be oriented toward inducing complete response.
Small primary de novo adenocarcinoma of the colon with mesenteric lymphatic metastasis
Authors: Jelinek Gary P. , Nava Hector R. , Nime Freda 
Published: February 2007

AbstractIt is felt that the majority of colorectal carcinomas develop by malignant degeneration of previously benign adenomatous polyps. A small primary colon carcinoma, thought to have developed de novo directly from the colonic mucosa without the usual polyp‐cancer sequence, is reported. This small nonulcerated lesion did not have the gross endoscopic appearance of a carcinoma and was associated with lymphatic metastasis. The need to include fiber‐optic colonoscopy as part of the routine preoperative work‐up and postoperative follow‐up to rule out synchronous and metachronous lesions not detected by barium contrast x‐ray studies is stressed.
Immunodiagnosis of tumors in vivo using radiolabeled monoclonal antibody A2B5
Authors: Reintgen Douglas S. , Shimizu Kazuo , Coleman Edward , Briner William , Kitzmiller John , Eisenbarth George , Seigler H. F. 
Published: February 2007

AbstractRecently a murine monoclonal antibody (A2B5) has been described that reacts with a membrane associated GQ ganglioside common to peptide secreting normal cells and tumors. In vitro binding data demonstrated the presence of this ganglioside on neurons, adrenal medulla, and pancreatic islets, along with neuroendocrine tumors such as insulinomas, pheochromocytomas, melanomas and neuroblastomas. Negative binding has previously been shown for tissue sections from liver, kidney, colon, lung, stomach, and tumors not derived from the neural crest. Because of the specificity at A2B5 in vitro, this monoclonal antibody was labeled with 131I for in vivo tumor localization studies. Daily radionuclear scans were obtained in 5 KX rats bearing the radiation induced rat insulinoma with disappearance of the label from the blood pool and concentration in the tumor so that by the fourth day, the only activity present by scan was in the insulinoma. Tissue‐counting data showed tumor/blood ratios (av ± SE, 1.29 ± 0.25) of A2B5 activity two to ten times the average activity found in other organs (0.28 ± 0.05). No tumor concentration of the control nonspecific monoclonal antibody P3X63 was evident (0.27 ± 0.04). In addition A2B5 also localized to five different human melanoma cells lines grown in nude mice with high tumor/blood levels (1.04 ± 0.27) compared to normal tissues (0.32 ± 0.05) (P = .0005), while no localization is seen in nudes carrying osteosarcomas, colon, bladder, and renal cell carcinomas. In addition antibody A2B5 did not concentrate in any normal tissue though the antigen is present on several. The finding that A2B5 reacts across species lines (mouse, rat, man) lends itself to obvious diagnostic and therapeutic possibilities.
Hibernoma: Ultrastructural observations
Authors: Fleishman Jay S. , Schwartz Robert Allen 
Published: February 2007

AbstractA light and electron microscopic study of a hibernoma and a brief discussion of the functional role of brown fat are presented. The multivacuolar cells composing brown fat have central round nuclei with prominent nucleoli. The quantity of mitochondria and lipid droplets in the cytoplasm of the cells varies considerably. The electron microscopic findings of hibernoma include multivacuolated and univacuolated cells with varying numbers of lipid vacuoles, lysosomes, lipofuscin granules, pinocytotic vesicles, and possibly prominent subplasmalemmal condensations. Interesting findings in this case include the presence of amorphous diastase resistant perodic acid (PAS) Schiff positive peripheral cytoplasmic masses which are variable in size and shape. These collections also appear extra‐cellularly. The presence of these masses, presumably composed of neutral mucopolysaccharides, has not, to our knowledge, been recorded previously.
The relationship of histamine H2 receptor‐bearing suppressor cells with the growth and metastasis of FANFT‐induced bladder cancer
Authors: Babayan Richard K. , Osband Michael E. , Carpinito Gennaro A. , Ho Zheng Sen , Cohen Ellen B. , Krane Robert J. 
Published: February 2007

AbstractA poorly differentiated transitional cell carcinoma in C3H/He mice results from the oral ingestion of the urinary tract carcinogen FANFT. This model, designated MBT2, is readily transplantable into syngeneic animals and has proven to be very useful in the development of chemotherapy. Prior to the use of this model for the testing of potential immunotherapeutic strategies, we have attempted to characterize the immunobiology of this tumor line. We report that the primary growth of this tumor in the footpad and its metastasis to lung are correlated with the development of increased numbers of suppressor cells, characterized by the expression of a surface histamine H2 receptor. These cells are originally evident in spleen and become maximal approximately 4 weeks after tumor implantation. This is followed by the migration of these cells from spleen to peripheral blood, an event that parallels the growth and eventual metastasis of this implanted transitional cell carcinoma. These events may have important significance for the development of immunomodulating therapy against bladder cancer.
Human breast cancer and impaired NK cell function
Authors: Garner Warren L. , Minton John P. , James Arthur G. , Hoffmann C. C. 
Published: February 2007

AbstractRecent advances in tumor immunology have led to the discovery of a new lymphoid cell with unique antitumor activity. Natural killer (NK) cells form an antitumor surveillance system and appear to be vital in preventing tumor growth and metastasis in animal models. We studied NK activity in patients with benign and malignant breast disease, using a chromium‐51 release microtiter cytotoxicity assay with K562 cells as targets. Compared with benign controls, patients with malignancies had significantly depressed NK‐mediated lysis (P < 0.01). Furthermore, lysis in those with advanced disease (stages II, III, and IV) was significantly less than in those with limited disease (stage I) (P < 0.01). NK activity was not correlated to estrogen or progesterone receptor states. Positive correlation of a depressed natural killer activity with the extent of tumor spread supports the concept of an NK cell immune surveillance system in breast cancer and emphasizes its importance in this malignancy.
The search for a consensus for early detection of bilateral seminoma
Authors: Danielli Lavy 
Published: February 2007

AbstractA case of bilateral seminoma of the the testis is presented that occured after a lag period of six years following right orchiectomy, even with correct cobalt therapy. The question of early detection of seminoma in the other testis is posed. A common consensus for repeat biopsies to detect new tumor growth should be determined.
Pancoast syndrome caused by extramedullary plasmacytoma
Authors: Chen Karl T. K. , Padmanabhan A. 
Published: February 2007

AbstractA 61‐year‐old patient had the clinical findings of Pancoast syndrome with shoulder pain, weakness and atrophy of hand muscles, and an opacified area in the apical lung field. Unlike most cases with Pancoast syndrome in which the tumors are primary carcinomas of the lung, the present case was shown to have a plasmacytoma involving the apical parietal pleura and the adjacent chest wall. The need for histologic diagnosis before treating patients with Pancoast syndrome is emphasized.
Multiple primary carcinoma of the lung
Authors: Chung Tae Soo 
Published: February 2007

AbstractThe risk of developing multiple primary lung carcinoma is rare (1.07%) but increases with time following resection of the first primary lesion. Eight well‐documented cases are reported along with a review of 351 cases reported in the literature. The interval between metachronous lesions ranged from 9 months to 17 years. Surgical resection remains the preferred treatment of resectable nonsmall cell carcinoma, with 5 year survival of 11%. All patients with lung carcinoma should be followed‐up for the rest of their lives because of the possible occurrence of a second primary.
The syndrome of inappropriate ADH secretion secondary to vinblastine‐bleomycin therapy
Authors: Ravikumar Thanjavur S. , Grage Theodor B. 
Published: February 2007

AbstractA clinical picture compatible with the syndrome of inappropriate ADH (antidiuretic hormone) secretion was observed in two patients receiving vinblastine‐bleomycin chemotherapy. The mechanism by which this response is brought about is unclear. Penetration of Vinka alkaloids into CSF of humans is poor in the absence of extensive meningeal involvement, and hence an indirect method of action by a reduction in the osmotic threshold for vasopressin release has been suggested. By administering vinblastine on days 1 and 4 (instead of days 1 and 2, as suggested in the high‐respoonse regimen consisting of vinblastine, bleomycin, and cis‐platinum) we have found better bone marrow tolerance and have not noticed the inappropriate ADH syndrome.
Is medullary carcinoma of the breast hormone dependent?
Authors: Patel J. K. , Nemoto T. , Dao T. L. 
Published: February 2007

AbstractFrom 1951 to 1981, 22 patients with metastatic medullary carcinoma of the breast were treated with hormonal therapies at Roswell Park Memorial Institute. Bilateral oophorectomy was performed in 6 premenopausal patients, and none had objective response, although one patient did have stable diseases for 7 months. Three of these patients subsequently underwent bilateral adrenalectomy and none responded. Thirteen of 16 postmenopausal patients underwent bilateral adrenalectomy and only one had an objective response of 4 months. Eight of 22 patients recived additive hormones, and one patient was treated with Tamoxifen. There was no objective response to these therapies. From this study, it appears that medullary carcinoma of the breast is less often responsive to endocrine therapy, and this finding correlates well with the recent data showing lower frequency of estrogen receptor‐positive tumors in these patients.